Cedric Francois Sells 10,186 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 10,186 shares of the firm’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $22.19, for a total value of $226,027.34. Following the transaction, the chief executive officer owned 321,419 shares in the company, valued at approximately $7,132,287.61. This trade represents a 3.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $19.94 on Friday. The company has a market cap of $2.52 billion, a price-to-earnings ratio of 64.32 and a beta of 0.31. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $31.17. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The stock has a fifty day moving average price of $22.89 and a 200-day moving average price of $23.41.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Thursday, October 30th. The company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The company had revenue of $458.58 million for the quarter, compared to analysts’ expectations of $364.58 million. During the same quarter last year, the business earned ($0.46) earnings per share. Apellis Pharmaceuticals’s revenue was up 133.0% on a year-over-year basis. As a group, equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

More Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo reiterated a Buy on Apellis, signaling continued confidence in the company’s longer‑term commercial execution and pipeline upside — a supportive voice for holders focused beyond near‑term sales. Read More.
• Positive Sentiment: Stifel Nicolaus issued a Buy on APLS (or reiterated constructive coverage), adding a second favorable analyst view that could help stabilize valuation if execution improves. Read More.
• Neutral Sentiment: Analysts remain mixed on Apellis: some see upside from Syfovre rollout and nephrology expansion while others emphasize near‑term sales risk and valuation — expect continued divergent research notes and volatile price reactions to company updates. Read More.
• Negative Sentiment: Apellis reported preliminary Q4 U.S. net product revenue of $190M and flagged weaker Syfovre sales with mixed Empaveli uptake — the main near‑term driver cited for a recent sharp weekly decline in the stock. Read More.
• Negative Sentiment: Major research houses (Cantor Fitzgerald, Needham) issued more pessimistic forecasts or lowered expectations, increasing downward pressure by reducing modeled revenues and price targets. Read More. Read More.
• Negative Sentiment: Significant insider selling on Jan. 13: multiple senior execs (CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others) sold shares at ~ $22.19 — filings show they still retain large stakes but the volume of disposals can be perceived negatively by the market. Read More.
• Negative Sentiment: Options flow indicated a large spike in put buying (reported >500% increase in put volume), reflecting elevated hedging and bearish positioning that can amplify short‑term volatility and downside pressure. Source: options flow reports

Institutional Investors Weigh In On Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC raised its position in Apellis Pharmaceuticals by 80.0% in the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after purchasing an additional 855 shares during the last quarter. Jones Financial Companies Lllp boosted its position in Apellis Pharmaceuticals by 206.8% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after buying an additional 1,373 shares during the period. Allworth Financial LP grew its holdings in Apellis Pharmaceuticals by 64.1% during the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock worth $50,000 after acquiring an additional 857 shares during the last quarter. Osaic Holdings Inc. increased its position in Apellis Pharmaceuticals by 141.2% in the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after acquiring an additional 1,570 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Apellis Pharmaceuticals during the third quarter worth $64,000. Institutional investors own 96.29% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on APLS. Mizuho reduced their price target on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Wells Fargo & Company initiated coverage on Apellis Pharmaceuticals in a report on Wednesday, October 15th. They issued an “overweight” rating and a $32.00 target price on the stock. Needham & Company LLC decreased their price target on Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday. Citigroup dropped their price objective on Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Finally, Robert W. Baird lifted their target price on Apellis Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Eleven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $33.65.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.